0001140361-22-014868.txt : 20220418 0001140361-22-014868.hdr.sgml : 20220418 20220418163040 ACCESSION NUMBER: 0001140361-22-014868 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220418 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220418 DATE AS OF CHANGE: 20220418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 22832457 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 brhc10036367_8k.htm CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 18, 2022

BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)


Delaware
1-1136
22-0790350
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)

430 East 29th Street, 14th Floor
New York, NY, 10016
(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (212) 546-4200


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 Par Value
BMY
New York Stock Exchange
1.000% Notes due 2025
BMY25
New York Stock Exchange
1.750% Notes due 2035
BMY35
New York Stock Exchange
Celgene Contingent Value Rights
CELG RT
New York Stock Exchange
     

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02
Results of Operations and Financial Condition.

Beginning with the first quarter of 2022, Bristol-Myers Squibb Company (the “Company”) will modify its presentation of non-GAAP results and no longer exclude from non-GAAP results significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights. These specified R&D charges that were previously excluded from non-GAAP results, as well as similar but less material charges that were previously included in non-GAAP results, will also be presented in a new financial statement line item labeled Acquired IPRD. The Company is making these changes to its presentation of non-GAAP financial measures following comments from, and discussions with, the U.S. Securities and Exchange Commission (the “SEC”). Prior period results will be revised to conform to the new presentation. Furnished pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein in their entirety are the revised presentation of the Company’s results of operations under GAAP to reflect the reclassification of the R&D charges from R&D expense to the new Acquired IPRD financial statement line item, the reconciliation to previously reported non-GAAP diluted earnings per share, the revised summary of specified items, and the revised reconciliation to non-GAAP results, in each case for the year ended December 31, 2020, each of the four quarters of 2021 and the year ended December 31, 2021.

GAAP and non-GAAP earnings per share is expected to include the net negative impact of approximately $0.10 per share during the first quarter of 2022 for Acquired IPRD charges and licensing income resulting from upfront and contingent milestone payments in connection with asset acquisitions or licensing of third party intellectual property rights. Results for the quarter ended March 31, 2022 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from this preliminary estimate.

Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by the Company under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

Cautionary Statement Regarding Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act, including with respect to the Company’s anticipated charges related to Acquired IPRD for the quarter ended March 31, 2022, and the related impact to the Company’s GAAP and non-GAAP earnings per share. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, completion of the Company’s quarter-end closing process, including review by management and the audit committee of the Company’s board of directors, which could result in changes to the Company’s preliminary estimates described herein. No forward-looking statement can be guaranteed. Forward-looking statements in this Current Report should be evaluated together with the many risks and uncertainties that affect the Company’s business and market, particularly those identified in the cautionary statement and risk factors discussion in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as updated by its subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. The forward-looking statements included in this Current Report are made only as of the date of this Current Report and except as otherwise required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Item 9.01.
Financial Statements and Exhibits.

 (d) Exhibits

The following exhibits are included as part of this Current Report on Form 8-K:

Exhibit
No.
  
Description
   
99.1
  
Revised presentation of the Company’s result of operations under GAAP, the reconciliation to previously reported non-GAAP diluted earnings per share, the revised summary of specified items, and the revised reconciliation to non-GAAP results, in each case for the year ended December 31, 2020, each of the four quarters of 2021 and the year ended December 31, 2021.
     
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

EXHIBIT INDEX

Exhibit
No.
  
Description
   
 
Revised presentation of the Company’s result of operations under GAAP, the reconciliation to previously reported non-GAAP diluted earnings per share, the revised summary of specified items, and the revised reconciliation to non-GAAP results, in each case for the year ended December 31, 2020, each of the four quarters of 2021 and the year ended December 31, 2021.
     
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BRISTOL-MYERS SQUIBB COMPANY
   
Dated: April 18, 2022
By:
/s/ Kimberly M. Jablonski
 
Name:
Kimberly M. Jablonski
 
Title:
Corporate Secretary


EX-99.1 2 brhc10036367_ex99-1.htm REVISED PRESENTATION OF FINANCIAL RESULTS
Exhibit 99.1

BRISTOL-MYERS SQUIBB COMPANY
EARNINGS FROM OPERATIONS
(Unaudited, dollars and shares in millions except per share data)

 
  
2020
    
2021
  
 
  
Year
    
1st Qtr
    
2nd Qtr
    
3rd Qtr
    
4th Qtr
    
Year
  
Net product sales
  
$
41,321
    
$
10,798
    
$
11,405
    
$
11,243
    
$
11,609
    
$
45,055
  
Alliance and other revenues
    
1,197
      
275
      
298
      
381
      
376
      
1,330
  
Total Revenues
    
42,518
      
11,073
      
11,703
      
11,624
      
11,985
      
46,385
  
 
                                                
Cost of products sold(a)
    
11,773
      
2,841
      
2,452
      
2,291
      
2,356
      
9,940
  
Marketing, selling and administrative
    
7,661
      
1,666
      
1,882
      
1,788
      
2,354
      
7,690
  
Research and development(b)
    
10,048
      
2,219
      
2,478
      
2,980
      
2,518
      
10,195
  
Acquired IPRD(b)
    
12,533
      
6
      
793
      
271
      
89
      
1,159
  
Amortization of acquired intangible assets
    
9,688
      
2,513
      
2,547
      
2,546
      
2,417
      
10,023
  
Other (income)/expense, net
    
(2,314
)
    
(702
)
    
(2
)
    
(409
)
    
393
      
(720
)
Total Expenses
    
49,389
      
8,543
      
10,150
      
9,467
      
10,127
      
38,287
  
 
                                                
Earnings Before Income Taxes
    
(6,871
)
    
2,530
      
1,553
      
2,157
      
1,858
      
8,098
  
Provision for Income Taxes
    
2,124
      
501
      
492
      
605
      
(514
)
    
1,084
  
 
                                                
Net Earnings
    
(8,995
)
    
2,029
      
1,061
      
1,552
      
2,372
      
7,014
  
Noncontrolling Interest
    
20
      
8
      
6
      
6
       —      
20
  
Net Earnings Attributable to BMS
  
$
(9,015
)
  
$
2,021
    
$
1,055
    
$
1,546
    
$
2,372
    
$
6,994
  
 
                                                
Diluted Earnings/(Loss) per Common Share*
  
$
(3.99
)
  
$
0.89
    
$
0.47
    
$
0.69
    
$
1.07
    
$
3.12
  
 
                                                
Weighted-Average Common Shares Outstanding - Diluted
    
2,258
      
2,265
      
2,252
      
2,243
      
2,219
      
2,245
  

* Quarterly amounts may not add to the year-to-date amounts, as each period is computed on a discrete basis.
(a) Excludes amortization of acquired intangible assets.
(b) Research and development charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights have been reclassified to the Acquired IPRD line item beginning with the first quarter of 2022. Prior period results have been revised for comparability.

BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION TO PREVIOUSLY REPORTED DILUTED EPS - NON-GAAP
(Unaudited, dollars and shares in millions except per share data)

 
  
2020
    
2021
  
 
  
Year
    
1st Qtr
    
2nd Qtr
    
3rd Qtr
    
4th Qtr
    
Year
  
Up-front and milestone charges previously specified
  
$
12,441
    
$
 —    
$
780
    
$
200
    
$
 —    
$
980
  
Licensing income previously specified
    
(168
)
    
(14
)
    
(15
)
     —      
(43
)
    
(72
)
Decrease/(Increase) in Earnings before income taxes - Non-GAAP
    
12,273
      
(14
)
    
765
      
200
      
(43
)
    
908
  
Income tax impact
    
(90
)
    
3
      
(96
)
    
(46
)
    
10
      
(129
)
Decrease/(Increase) in Net earnings attributable to BMS - Non-GAAP
    
12,183
      
(11
)
    
669
      
154
      
(33
)
    
779
  
 
                                                
Decrease/(Increase) in Diluted Earnings Per Share - Non-GAAP
    
5.31
      
—
   
0.30
      
0.07
      
(0.01
)
    
0.35
  
Diluted Earnings Per Share - Non-GAAP previously reported
    
6.44
      
1.74
      
1.93
      
2.00
      
1.83
      
7.51
  
Revised Diluted Earnings Per Share - Non-GAAP
    
1.13
      
1.74
      
1.63
      
1.93
      
1.84
      
7.16
  

BRISTOL-MYERS SQUIBB COMPANY
SPECIFIED ITEMS
(Unaudited, dollars in millions)

 
  
2020(a)
    
2021(a)
  
 
  
Year
    
1st Qtr
    
2nd Qtr
    
3rd Qtr
    
4th Qtr
    
Year
  
Inventory purchase price accounting adjustments
  
$
2,688
    
$
79
    
$
88
    
$
97
    
$
 —    
$
264
  
Intangible asset impairment
    
575
      
315
      
—
      
—
      
—
      
315
  
Employee compensation charges
    
4
      
—
      
—
      
—
      
—
      
—
  
Site exit and other costs
    
33
      
23
      
1
      
—
      
—
      
24
  
Cost of products sold
    
3,300
      
417
      
89
      
97
      
—
      
603
  
 
                                                
Employee compensation charges
    
275
      
—
      
1
      
—
      
—
      
1
  
Site exit and other costs
    
4
      
(1
)
    
—
      
1
      
2
      
2
  
Marketing, selling and administrative
    
279
      
(1
)
    
1
      
1
      
2
      
3
  
 
                                                
IPRD impairments
    
470
      
—
      
230
      
610
      
—
      
840
  
Inventory purchase price accounting adjustments
    
36
      
—
      
—
      
1
      
—
      
1
  
Employee compensation charges
    
282
      
1
      
—
      
—
      
—
      
1
  
Site exit and other costs
    
115
      
—
      
—
      
1
      
—
      
1
  
Research and development
    
903
      
1
      
230
      
612
      
—
      
843
  
 
                                                
Amortization of acquired intangible assets
    
9,688
      
2,513
      
2,547
      
2,546
      
2,417
      
10,023
  
 
                                                
Interest expense(b)
    
(159
)
    
(34
)
    
(28
)
    
(29
)
    
(29
)
    
(120
)
Contingent consideration
    
(1,757
)
    
(510
)
    
—
      
—
      
(32
)
    
(542
)
Equity investment (gains)/losses
    
(1,156
)
    
(608
)
    
(154
)
    
(465
)
    
469
      
(758
)
Integration expenses
    
717
      
141
      
152
      
141
      
130
      
564
  
Provision for restructuring
    
530
      
45
      
78
      
27
      
19
      
169
  
Litigation and other settlements
    
(239
)
    
—
      
—
      
—
      
—
      
—
  
Reversion excise tax
    
76
      
—
      
—
      
—
      
—
      
—
  
Divestiture (gains)/losses
    
(55
)
    
—
      
(11
)
    
2
      
—
      
(9
)
Loss on debt redemption
    
—
      
281
      
—
      
—
      
—
      
281
  
Other (income)/expense, net
    
(2,043
)
    
(685
)
    
37
      
(324
)
    
557
      
(415
)
 
                                                
Increase to pretax income
    
12,127
      
2,245
      
2,904
      
2,932
      
2,976
      
11,057
  
 
                                                
Income taxes on items above
    
(1,643
)
    
(303
)
    
(292
)
    
(137
)
    
(261
)
    
(993
)
Income taxes attributed to Otezla divestiture
    
266
      
—
      
—
      
—
      
—
      
—
  
Income taxes attributed to internal transfer of intangible assets
    
853
      
—
      
—
      
—
      
(983
)
    
(983
)
Income taxes
    
(524
)
    
(303
)
    
(292
)
    
(137
)
    
(1,244
)
    
(1,976
)
 
                                                
Increase to net earnings
  
$
11,603
    
$
1,942
    
$
2,612
    
$
2,795
    
$
1,732
    
$
9,081
  
 
(a)
Revised to exclude significant R&D charges or other income resulting from up-front and contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights (including related income tax impacts).
(b)
Includes amortization of purchase price adjustments to Celgene debt.

BRISTOL-MYERS SQUIBB COMPANY
RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS
(Unaudited, dollars in millions)

 
  
2020
    
2021
  
 
  
Year
    
1st Qtr
    
2nd Qtr
    
3rd Qtr
    
4th Qtr
    
Year
  
Gross profit
  
$
30,745
    
$
8,232
    
$
9,251
    
$
9,333
    
$
9,629
    
$
36,445
  
Specified items (a)
    
3,300
      
417
      
89
      
97
      
—
      
603
  
Gross profit excluding specified items
    
34,045
      
8,649
      
9,340
      
9,430
      
9,629
      
37,048
  
 
                                                
Marketing, selling and administrative
    
7,661
      
1,666
      
1,882
      
1,788
      
2,354
      
7,690
  
Specified items (a)
    
(279
)
    
1
      
(1
)
    
(1
)
    
(2
)
    
(3
)
Marketing, selling and administrative excluding specified items
    
7,382
      
1,667
      
1,881
      
1,787
      
2,352
      
7,687
  
 
                                                
Research and development
    
10,048
      
2,219
      
2,478
      
2,980
      
2,518
      
10,195
  
Specified items (a)
    
(903
)
    
(1
)
    
(230
)
    
(612
)
    
—
      
(843
)
Research and development excluding specified items
    
9,145
      
2,218
      
2,248
      
2,368
      
2,518
      
9,352
  
 
                                                
Amortization of acquired intangible assets
    
9,688
      
2,513
      
2,547
      
2,546
      
2,417
      
10,023
  
Specified items (a)
    
(9,688
)
    
(2,513
)
    
(2,547
)
    
(2,546
)
    
(2,417
)
    
(10,023
)
Amortization of acquired intangible assets excluding specified items
    
—
      
—
      
—
      
—
      
—
      
—
  
 
                                                
Other (income)/expense, net
    
(2,314
)
    
(702
)
    
(2
)
    
(409
)
    
393
      
(720
)
Specified items (a)
    
2,043
      
685
      
(37
)
    
324
      
(557
)
    
415
  
Other (income)/expense, net excluding specified items
    
(271
)
    
(17
)
    
(39
)
    
(85
)
    
(164
)
    
(305
)
 
                                                
Earnings/(Loss) before income taxes
    
(6,871
)
    
2,530
      
1,553
      
2,157
      
1,858
      
8,098
  
Specified items(a)
    
12,127
      
2,245
      
2,904
      
2,932
      
2,976
      
11,057
  
Earnings before income taxes excluding specified items
    
5,256
      
4,775
      
4,457
      
5,089
      
4,834
      
19,155
  
 
                                                
Provision/(benefit) for income taxes
    
2,124
      
501
      
492
      
605
      
(514
)
    
1,084
  
Income taxes on specified items(a)
    
1,643
      
303
      
292
      
137
      
261
      
993
  
Income taxes attributed to Otezla® divestiture(a)
    
(266
)
    
—
      
—
      
—
      
—
      
—
  
Income taxes attributed to internal transfer of intangible assets(a)
    
(853
)
    
—
      
—
      
—
      
983
      
983
  
Provision for income taxes excluding tax on specified items and income taxes attributed to Otezla® divestiture and internal transfer of intangible assets
    
2,648
      
804
      
784
      
742
      
730
      
3,060
  
 
                                                
Noncontrolling Interest
    
20
      
8
      
6
      
6
      
—
      
20
  
Specified items(a)
    
—
      
—
      
—
      
—
      
—
      
—
  
Noncontrolling Interest excluding specified items
    
20
      
8
      
6
      
6
      
—
      
20
  
 
                                                
Net Earnings/(Loss) attributable to BMS used for Diluted EPS Calculation - GAAP
    
(9,015
)
    
2,021
      
1,055
      
1,546
      
2,372
      
6,994
  
Specified items(a)
    
11,603
      
1,942
      
2,612
      
2,795
      
1,732
      
9,081
  
Net earnings attributable to BMS used for Diluted EPS Calculation excluding specified items - Non-GAAP
    
2,588
      
3,963
      
3,667
      
4,341
      
4,104
      
16,075
  
 
                                                
Weighted-average Common Shares Outstanding - Diluted - GAAP
    
2,258
      
2,265
      
2,252
      
2,243
      
2,219
      
2,245
  
Weighted-average Common Shares Outstanding - Diluted - Non-GAAP
    
2,293
      
2,265
      
2,252
      
2,243
      
2,219
      
2,245
  
 
                                                
Diluted Earnings/(Loss) Per Share - GAAP*
  
$
(3.99
)
  
$
0.89
    
$
0.47
    
$
0.69
    
$
1.07
    
$
3.12
  
Diluted Earnings Per Share attributable to specified items(a)
    
5.12
      
0.85
      
1.16
      
1.24
      
0.77
      
4.04
  
Diluted Earnings Per Share - Non-GAAP*
  
$
1.13
    
$
1.74
    
$
1.63
    
$
1.93
    
$
1.84
    
$
7.16
  
 
                                                
Effective Tax Rate
    
(30.9
)%
    
19.8
%
    
31.7
%
    
28.0
%
    
(27.7
)%
    
13.4
%
Specified items(a)
    
81.3
%
    
(3.0
)%
    
(14.1
)%
    
(13.5
)%
    
42.8
%
    
2.6
%
Effective Tax Rate excluding specified items
    
50.4
%
    
16.8
%
    
17.6
%
    
14.6
%
    
15.1
%
    
16.0
%

*
Quarterly amounts may not add to the year-to-date amounts, as each period is computed on a discrete basis.
(a)
Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.

BRISTOL-MYERS SQUIBB COMPANY
USE OF NON-GAAP FINANCIAL INFORMATION

In discussing financial results, the Company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures, provided as supplemental information to the financial measures presented in this exhibit that are calculated and presented in accordance with GAAP, are presented because management has evaluated the Company’s financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented supplement or enhance management, analysts and investors overall understanding of the Company’s underlying financial performance and trends and facilitate comparisons among current, past and future periods.

Non-GAAP financial measures such as non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. These items are excluded from non-GAAP earnings and related EPS information because the Company believes they neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwind of inventory purchase price adjustments, acquisition and integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, divestiture gains or losses, stock compensation resulting from accelerated vesting of Celgene awards, certain retention-related employee compensation charges related to the Celgene transaction, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments beginning in 2021) and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. Certain other significant tax items are also excluded such as the impact resulting from internal transfers due to streamlining our legal entity structure subsequent to the Celgene acquisition and the global intangible low taxed income tax change upon finalization of the Otezla* divestiture in 2020. Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. The Company will modify its presentation of non-GAAP results and no longer exclude from non-GAAP results significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights beginning in the first quarter of 2022. For the purposes of comparability with future periods, the non-GAAP financial measures for the year ended December 31, 2020, each of the four quarters of 2021 and the year ended December 31, 2021, presented in this exhibit have been updated to reflect this change; however, the Company has reconciled non-GAAP diluted earnings per share as calculated using the new methodology to the previously reported non-GAAP diluted earnings per share to allow investors and readers to evaluate this non-GAAP measure using the historic methodologies in place as of the applicable dates.

Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to and are not intended to be considered in isolation or as a substitute for the related financial measures presented in this exhibit that are prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

Reconciliations of the non-GAAP financial measures to the most comparable GAAP measures are provided in the accompanying financial tables. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.


 EX-101.SCH 3 bmy-20220418.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bmy-20220418_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bmy-20220418_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Domain] Common Stock [Member] Class of Stock [Axis] Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Listings [Table] Entity Listings [Line Items] Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name 1.750% Notes due 2035 [Member] Celgene Contingent Value Rights [Member] 1.000% Notes due 2025 [Member] EX-101.PRE 6 bmy-20220418_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Apr. 18, 2022
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 18, 2022
Entity Registrant Name BRISTOL MYERS SQUIBB CO
Entity Incorporation, State or Country Code DE
Entity File Number 001-01136
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One 430 East 29th Street
Entity Address, Address Line Two 14th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10016
City Area Code 212
Local Phone Number 546-4200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000014272
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.000% Notes due 2025 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.000% Notes due 2025
Trading Symbol BMY25
Security Exchange Name NYSE
1.750% Notes due 2035 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY35
Security Exchange Name NYSE
Celgene Contingent Value Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Celgene Contingent Value Rights
Trading Symbol CELG RT
Security Exchange Name NYSE
XML 8 brhc10036367_8k_htm.xml IDEA: XBRL DOCUMENT 0000014272 2022-04-18 2022-04-18 0000014272 bmy:One750NotesDue2035Member 2022-04-18 2022-04-18 0000014272 bmy:CelgeneContingentValueRightsMember 2022-04-18 2022-04-18 0000014272 us-gaap:CommonStockMember 2022-04-18 2022-04-18 0000014272 bmy:One000NotesDue2025Member 2022-04-18 2022-04-18 false BRISTOL MYERS SQUIBB CO 001-01136 NY 0000014272 8-K 2022-04-18 DE 22-0790350 430 East 29th Street 14th Floor New York 10016 212 546-4200 false false false false Common Stock, $0.10 Par Value BMY NYSE 1.000% Notes due 2025 BMY25 NYSE 1.750% Notes due 2035 BMY35 NYSE Celgene Contingent Value Rights CELG RT NYSE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 5 23 1 false 4 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://bms.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports brhc10036367_8k.htm bmy-20220418.xsd bmy-20220418_def.xml bmy-20220418_lab.xml bmy-20220418_pre.xml brhc10036367_ex99-1.htm http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10036367_8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 5, "dts": { "definitionLink": { "local": [ "bmy-20220418_def.xml" ] }, "inline": { "local": [ "brhc10036367_8k.htm" ] }, "labelLink": { "local": [ "bmy-20220418_lab.xml" ] }, "presentationLink": { "local": [ "bmy-20220418_pre.xml" ] }, "schema": { "local": [ "bmy-20220418.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 37, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 5, "total": 5 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 3, "memberStandard": 1, "nsprefix": "bmy", "nsuri": "http://bms.com/20220418", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10036367_8k.htm", "contextRef": "c20220418to20220418", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://bms.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "brhc10036367_8k.htm", "contextRef": "c20220418to20220418", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 4, "tag": { "bmy_CelgeneContingentValueRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Celgene Contingent Value Rights [Member]" } } }, "localname": "CelgeneContingentValueRightsMember", "nsuri": "http://bms.com/20220418", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "bmy_One000NotesDue2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "1.000% Notes due 2025 [Member]" } } }, "localname": "One000NotesDue2025Member", "nsuri": "http://bms.com/20220418", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "bmy_One750NotesDue2035Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "1.750% Notes due 2035 [Member]" } } }, "localname": "One750NotesDue2035Member", "nsuri": "http://bms.com/20220418", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001140361-22-014868-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-014868-xbrl.zip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end